Vuurmans T, et al. - This study was designed to test the hypothesis that revascularization with either coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) leads to progression of renal failure, but improves survival compared with medical therapy in patients with chronic kidney disease (CKD). Findings revealed that progression of renal failure was higher in the first 3 months for CABG, but similar for all groups at 24 months in patients with coronary artery disease (CAD) and CKD who underwent the current practice of CABG, PCI, or are treated with medical therapy. In addition, in those treated with CABG vs PCI or medical therapy, lower 2-year mortality was noted.